scholarly journals Synthesis, in Vitro Pharmacology, and Molecular Modeling of Very Potent Tacrine−Huperzine A Hybrids as Acetylcholinesterase Inhibitors of Potential Interest for the Treatment of Alzheimer's Disease

1999 ◽  
Vol 42 (17) ◽  
pp. 3227-3242 ◽  
Author(s):  
Pelayo Camps ◽  
Rachid El Achab ◽  
Diana Marina Görbig ◽  
Jordi Morral ◽  
Diego Muñoz-Torrero ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Molecular Modeling ◽  
Acetylcholinesterase Inhibitors ◽  
Huperzine A ◽  
Potential Interest ◽  
In Vitro Pharmacology

Natural Anti-inflammatory compounds as Drug candidates in Alzheimer’s disease

2020 ◽  
Vol 27 ◽  
Author(s):  
Reyaz Hassan Mir ◽  
Abdul Jalil Shah ◽  
Roohi Mohi-ud-din ◽  
Faheem Hyder Potoo ◽  
Mohd. Akbar Dar ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Natural Products ◽  
Protective Action ◽  
New Drugs ◽  
Huperzine A ◽  
Brain Disorder ◽  
Anti Inflammatory

: Alzheimer's disease (AD) is a chronic neurodegenerative brain disorder characterized by memory impairment, dementia, oxidative stress in elderly people. Currently, only a few drugs are available in the market with various adverse effects. So to develop new drugs with protective action against the disease, research is turning to the identification of plant products as a remedy. Natural compounds with anti-inflammatory activity could be good candidates for developing effective therapeutic strategies. Phytochemicals including Curcumin, Resveratrol, Quercetin, Huperzine-A, Rosmarinic acid, genistein, obovatol, and Oxyresvertarol were reported molecules for the treatment of AD. Several alkaloids such as galantamine, oridonin, glaucocalyxin B, tetrandrine, berberine, anatabine have been shown anti-inflammatory effects in AD models in vitro as well as in-vivo. In conclusion, natural products from plants represent interesting candidates for the treatment of AD. This review highlights the potential of specific compounds from natural products along with their synthetic derivatives to counteract AD in the CNS.

Spirocyclohexadienones as an Uncommon Scaffold for Acetylcholinesterase Inhibitory Activity

2019 ◽  
Vol 15 (4) ◽  
pp. 373-382 ◽  
Author(s):  
Ralph C. Gomes ◽  
Renata P. Sakata ◽  
Wanda P. Almeida ◽  
Fernando Coelho
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Population Aging ◽  
Acetylcholinesterase Inhibitors ◽  
Acetylcholinesterase Activity ◽  
Docking Study ◽  
Biological Properties ◽  
Ache Inhibitor ◽  
Molecular Docking Study

Background: The most important cause of dementia affecting elderly people is the Alzheimer’s disease (AD). Patients affected by this progressive and neurodegenerative disease have severe memory and cognitive function impairments. Some medicines used for treating this disease in the early stages are based on inhibition of acetylcholinesterase. Population aging should contribute to increase the cases of patients suffering from Alzheimer's disease, thus requiring the development of new therapeutic entities for the treatment of this disease. Methods: The objective of this work is to identify new substances that have spatial structural similarity with donepezil, an efficient commercial drug used for the treatment of Alzheimer's disease, and to evaluate the capacity of inhibition of these new substances against the enzyme acetylcholinesterase. Results: Based on a previous results of our group, we prepared a set of 11 spirocyclohexadienones with different substitutions patterns in three steps and overall yield of up to 59%. These compounds were evaluated in vitro against acetylcholinesterase. We found that eight of them are able to inhibit the acetylcholinesterase activity, with IC50 values ranging from 0.12 to 12.67 µM. Molecular docking study indicated that the spirocyclohexadienone, 9e (IC50 = 0.12 µM), a mixedtype AChE inhibitor, showed a good interaction at active site of the enzyme, including the cationic (CAS) and the peripheral site (PAS). Conclusion: We described the first study aimed at investigating the biological properties of spirocyclohexadienones as acetylcholinesterase inhibitors. Thus, we have identified an inhibitor, which provided valuable insights for further studies aimed at the discovery of more potent acetylcholinesterase inhibitors.

Synthesis, Molecular Modeling, and Evaluation of Novel Sulfonylhydrazones as Acetylcholinesterase Inhibitors for Alzheimer's Disease

2017 ◽  
Vol 350 (11) ◽  
pp. 1700163 ◽  
Author(s):  
Thais B. Fernandes ◽  
Micael R. Cunha ◽  
Renata P. Sakata ◽  
Thalita M. Candido ◽  
André R. Baby ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Molecular Modeling ◽  
Acetylcholinesterase Inhibitors

scholarly journals New Tacrine−Huperzine A Hybrids (Huprines):  Highly Potent Tight-Binding Acetylcholinesterase Inhibitors of Interest for the Treatment of Alzheimer's Disease

2000 ◽  
Vol 43 (24) ◽  
pp. 4657-4666 ◽  
Author(s):  
Pelayo Camps ◽  
Rachid El Achab ◽  
Jordi Morral ◽  
Diego Muñoz-Torrero ◽  
Albert Badia ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Tight Binding ◽  
Acetylcholinesterase Inhibitors ◽  
Huperzine A

scholarly journals In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease

2018 ◽  
Vol 17 (1) ◽  
pp. 54-68 ◽  
Author(s):  
Kanzal Iman ◽  
Muhammad Usman Mirza ◽  
Nauman Mazhar ◽  
Michiel Vanmeert ◽  
Imran Irshad ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
In Silico ◽  
Neurodegenerative Disorder ◽  
In Silico Analysis ◽  
Acetylcholinesterase Inhibitors ◽  
Binding Energies ◽  
Therapeutic Interventions ◽  
Ache Inhibitors

Objective and Background: Inhibition of acetylcholinesterase (AChE) has gained much importance since the discovery of the involvement of peripheral anionic site as an allosteric regulator of AChE. Characterized by the formation of β-amyloid plaques, Alzheimer's disease (AD) is currently one of the leading causes of death across the world. Progression in this neurodegenerative disorder causes deficit in the cholinergic activity that leads towards cognitive decline. Therapeutic interventions in AD are largely focused upon AChE inhibitors designed essentially to prevent the loss of cholinergic function. The multifactorial AD pathology calls for Multitarget-directed ligands (MTDLs) to follow up on various components of the disease. Considering this approach, other related AD targets were also selected. Structure-based virtual screening was relied upon for the identification of lead compounds with anti-AD effect. Method: Several chemoinformatics approaches were used in this study, reporting four multi-target inhibitors: MCULE-7149246649-0-1, MCULE-6730554226-0-4, MCULE-1176268617-0-6 and MCULE-8592892575-0-1 with high binding energies that indicate better AChE inhibitory activity. Additional in-silico analysis hypothesized the abundant presence of aromatic interactions to be pivotal for interaction of selected compounds to the acetyl-cholinesterase. Additionally, we presented an alternative approach to determine protein-ligand stability by calculating the Gibbs-free energy change over time. Furthermore, this allows to rank potential hits for further in-vitro testing. Results and Conclusion: With no predicted indication of adverse effects on humans, this study unravels four active multi-target inhibitors against AChE with promising affinities and good ADMET profile for the potential use in AD treatment.

scholarly journals Evaluating the Acetylcholinesterase Inhibitory and Antioxidant Activities of Persea Americana Extracts

2019 ◽  
Vol 35 (1) ◽  
Author(s):  
Dang Kim Thu ◽  
Hoang Thu Thuy ◽  
Bui Thi Thanh Duyen ◽  
Luc Thi Thanh Hang ◽  
Nguyen Thi Trang ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Antioxidant Activities ◽  
Acetylcholinesterase Inhibitors ◽  
Antioxidant Effect ◽  
Seed Extract ◽  
Persea Americana ◽  
Ic50 Value ◽  
Ache Inhibitory Activity

Medicinal plants are a potential source of enzyme acetylcholinesrerase (AChE) inhibitors, a key target in the treatment of Alzheimer’s disease. This paper studies the AChE inhibitory activity and the antioxidant effect of Persea Americana Mill extract. The sample leave, seed, exocarp and mesocarp of avocado were extracted with 50% ethanol and subsequently fractionated with n-hexane, ethyl acetate (EtOA) and n-butanol (n-BuOH) solvents. The AChE inhibitory activity was evaluated by Ellman’s colorimetric method and the antioxidant activity by screening DPPH free radicals.  The results show that the seed of Persea Americana extract had the strongest AChE inhibitory activity and antioxidant effect, followed by the leave extract, and the exocarp extract and mesocarp extract were the weakest. The Persea Americana seed extract inhibited AChE activity in a dose-dependent manner with an IC50 value of 47.43 ± 0.5 μg/mL and the antioxidant effect with an IC50 value of 68.7 ± 0.35 µg/mL. The results also show that n–BuOH fraction of Persea Americana seed extract had strong AChE inhibitory and antioxidant activities with an IC50 value of 15.24 ± 0.52 µg/ml and 15.73 ± 0.42 μg/mL, respectively. The study results suggest that the Persea Americana Mill is a promising ingredient in Alzheimer’s disease prevention and treatment. Keywords Persea Americana Mill, Acetylcholinesrerase inhibitors (AChE), Alzheimer, DPPH. References [1] M.M. Essa et al., Neuroprotective effect of natural products against Alzheimer's disease, Neurochem Res. 37(9) (2012) 1829.[2] B. McGleenon, K. Dynan, A. Passmore,. Acetylcholinesterase inhibitors in Alzheimer's disease, British journal of clinical pharmacology. 48 (1999) 471.[3] P. B. Watkins et al, Hepatotoxic effects of tacrine administration in patients with Alzheimer's disease, In: Jama. pp. 992 (1994).[4] O. Adeyemi, S. Okpo, O. Ogunti,. Analgesic and anti-inflammatory effects of the aqueous extract of leaves of Persea americana Mill (Lauraceae). In: Fitoterapia. pp. 375 (2002).[5] P.D.D. Dzeufiet, et al, Antihypertensive potential of the aqueous extract which combine leaf of Persea americana Mill. (Lauraceae), stems and leaf of Cymbopogon citratus (DC) Stapf.(Poaceae), fruits of Citrus medical L.(Rutaceae) as well as honey in ethanol and sucrose experimental model. In: BMC complementary and alternative medicine. p. 507 (2014).[6] B.I. Brai, A. Odetola, P. Agomo,. Hypoglycemic and hypocholesterolemic potential of Persea americana leaf extracts, Journal of medicinal food. 10(2) (2007) 356.[7] Phạm Khuê. Bệnh Alzheimer. Nhà xuất bản Y học (2002).[8] Đàm Trung Bảo. Các gốc tự do, Tạp chí Dược học. 6 (2001) 29 [9] F.R. Mowsumi, A. Rahaman, N.C. Sarker, B.K. Choudhury, S. Hossain, In vitro relative free radical scavenging effects of Calocybe indica (milky oyster) and Pleurotus djamor (pink oyster), World J Pharm Pharm Sci. 4(07) (2015) 186.[10] Y. Bao, Y. Qu, J. Li, Y. Li, X. Ren, K. Maffuci, et al. In vitro and in vivo antioxidant activities of the flowers and leaves from Paeonia rockii and identification of their antioxidant constituents by UHPLC-ESI-HRMSn via pre-column DPPH reaction, Molecules. 23(2) (2018) 392.[11] Phan Kế Sơn. Đánh giá tác dụng ức chế enzym Acetylcholinsterase in vitro của các phân đoạn dịch chiết Hoàng Liên Ô rô (Mahonia Nepalensis DC., họ Berberidaceae). Khóa luận tốt nghiệp Đại học ngành Dược học. Khoa Y Dược - Đại học Quốc Gia Hà Nội (2017).[12] D. Mohammad, P. Chan, J. Bradley, K. Lanctôt, N. Herrmann, Acetylcholinesterase inhibitors for treating dementia symptoms-a safety evaluation, Expert opinion on drug safety. 16(9) (2017) 1009.[13] A. Mohammadi-Farani, S.S. Darbandi, A. Aliabadi, Synthesis and acetylcholinesterase inhibitory evaluation of 4-(1, 3-dioxoisoindolin-2-yl)-N-phenyl benzamide derivatives as potential anti-alzheimer agents, Iranian journal of pharmaceutical research. IJPR 15(3) (2016) 313.[14] T.B. Fernandes, M.R. Cunha, R.P. Sakata, T.M. Candido, A.R. Baby, M.T. Tavares, et al. Synthesis, Molecular Modeling, and Evaluation of Novel Sulfonylhydrazones as Acetylcholinesterase Inhibitors for Alzheimer's Disease, Archiv der Pharmazie. 350(11) (2017) 1700163.[15] M.I. Alkhalf, W.S. Alansari, E.A. Ibrahim, M.E. Elhalwagy, Anti-oxidant, anti-inflammatory and anti-cancer activities of avocado (Persea americana) fruit and seed extract. Journal of King Saud University-Science (2018).[16] F. Gómez, S. Sánchez, M. Iradi, N. Azman, M. Almajano, Avocado seeds: extraction optimization and possible use as antioxidant in food, Antioxidants. 3(2) (2014) 439.[17] O.A. Folasade, R.A. Olaide, T.A. Olufemi, Antioxidant properties of Persea americana M. seed as affected by different extraction solvent, Journal of Advances in Food Science & Technology. 3(2) (2016) 101.[18] C.A. Alagbaoso, I.I. Tokunbo, O.S. Osakwe, Comparative study of antioxidant activity and mineral composition of methanol extract of seeds of ripe and unripe avocado pear (Persea americana, Mill.). NISEB Journal. 15(4) (2017).[19] G. Oboh, V.O. Odubanjo, F. Bello, A.O. Ademosun, S.I. Oyeleye, E.E. Nwanna et al. Aqueous extracts of avocado pear (Persea americana Mill.) leaves and seeds exhibit anti-cholinesterases and antioxidant activities in vitro, Journal of basic and clinical physiology and pharmacology. 27(2) (2016) 131.[20] H. Cavdar, M. Senturk, M. Guney , S. Durdagi, G. Kayik, C.T. Supuran, et al. Inhibition of acetylcholinesterase and butyrylcholinesterase with uracil derivatives: kinetic and computational studies, Journal of enzyme inhibition and medicinal chemistry. 34(1) (2019) 429.    

Sign in / Sign up

Export Citation Format

Share Document